Skip to Main Content


Current Issue
Volume 136,
Issue 6,
August 6, 2020

Issue Highlights

Latest in Blood
Free Articles
John Strouboulis
DOI: 10.1182/blood.2020006107
Plenary Papers
Lauren K. Meyer; Katherine C. Verbist; Sabrin Albeituni; Brooks P. Scull; Rachel C. Bassett; Alexa N. Stroh; Heather Tillman; Carl E. Allen; Michelle L. Hermiston; Kim E. Nichols
DOI: 10.1182/blood.2020006075
First Edition
Imene Melki; Isabelle Allaeys; Nicolas Tessandier; Benoit Mailhot; Nathalie Cloutier; Robert A. Campbell; Jesse W Rowley; David Salem; Anne Zufferey; Audrée Laroche; Tania Lévesque; Natalie Patey; Joyce Rauch; Christian Lood; Arnaud Droit; Steven E. McKenzie; Kellie R Machlus; Matthew T. Rondina; Steve Lacroix; Paul Fortin; Eric Boilard
DOI: 10.1182/blood.2020004974
Clinical Trials and Observations
Seok Jin Kim; Jing Quan Lim; Yurike Laurensia; Junhun Cho; Sang Eun Yoon; Ji Young Lee; Kyung Ju Ryu; Young Hyeh Ko; Youngil Koh; Duck Cho; Soon Thye Lim; Marie Beck Enemark; Francesco D'amore; Mette Bjerre; Choon Kiat Ong; Won Seog Kim
DOI: 10.1182/blood.2020007247


Message from ASH President on Diversity, Equity, and Inclusion

Authors and Reviewers: New COVID-19 Announcement

Featured Content

Blood Podcast: Season 1, Episode 32

In this week’s episode we will review a study exploring the use of a novel hemophilia A mouse model to examine emicizumab function in vivo, a new approach to fighting the cytokine storm of HLH with a combination of glucocorticoids and ruxolitinib, and a timely Letter to Blood about red cell-bound antibodies and transfusion requirements in hospitalized patients with COVID-19.

JAK/STAT pathway inhibition sensitizes CD8 T cells to dexamethasone-induced apoptosis in hyperinflammation

In a Plenary Paper, the authors demonstrate that cytokine-induced JAK/STAT signaling mediates cell resistance to dexamethasone and that glucocorticoid-induced apoptosis can be reestablished with the JAK inhibitor ruxolitinib. This suggests that dexamethasone plus ruxolitinib is a potent combination for treating hemophagocytic lymphohistiocytosis (HLH) and other cytokine storm–related syndromes.

LUBAC accelerates B-cell lymphomagenesis by conferring resistance to genotoxic stress on B cells

Diffuse large B-cell lymphoma of the activated B-cell type (ABC-DLBCL) often overexpresses linear ubiquitin chain assembly complex (LUBAC). Jo et al studied a mouse model of LUBAC overexpression, demonstrating that LUBAC cooperates with MYD88 to promote lymphomagenesis and can be targeted by a LUBAC-specific inhibitor. Since MYD88-mutated ABC-DLBCL often overexpresses LUBAC, this study suggests a potential new approach to therapy for these poor-prognosis lymphomas.

Human erythroleukemia genetics and transcriptomes identify master transcription factors as functional disease drivers

Fagnan et al studied the genetic landscape of acute erythroleukemia (AEL) in a cohort of 33 patient samples. Transcriptomics confirm that these leukemias segregate into 3 subgroups. The authors discerned a shared AEL-specific pattern of aberrant expression of regulators of erythroid differentiation converging on repression of GATA1 activity.

Hepatic transferrin plays a role in systemic iron homeostasis and liver ferroptosis

Yu et al dissected the complex role of transferrin in maintaining iron homeostasis. In elegant mouse studies, they demonstrated that transferrin, which is synthesized primarily in the liver, is important in blocking hepatic iron accumulation. Liver-specific transferrin knockout mice develop severe iron overload and hepatic fibrosis that can be blocked by deleting a second iron transporter, Slc39a14.

A hemophilia A mouse model for the in vivo assessment of emicizumab function

The bispecific antibody emicizumab bridges factor IXa and factor X, effectively replacing the function of factor VIII in hemophilia A, but measurement of factor VIII activity is inaccurate in the presence of the drug. Using a novel approach in a hemophilia mouse model, Ferrière et al confirmed that emicizumab generates a factor VIII activity equivalent to about 9% and that small doses of factor VIII greatly enhance its efficacy against bleeding, providing a platform for optimizing therapy.

Close Modal
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close Modal
Close Modal